Human Vaccines & Immunotherapeutics Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine - Institut Pasteur Access content directly
Journal Articles Human Vaccines & Immunotherapeutics Year : 2016

Human Vaccines & Immunotherapeutics Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine

Abstract

Neisseria meningitidis serogroup B is the most prevalent cause of invasive meningococcal disease in Europe and members of laboratories working on meningococci are at risk due to frequent handling. Recommendation for anti-meningococcal vaccination among these workers has been recently updated upon the licensure in Europe of Bexsero® vaccine. We tested the immunogenicity and safety of this vaccine among adults laboratory staff using the recommended schedule of 2 doses at 5 weeks interval. The vaccine was well tolerated in spite of frequent local side effects and all participants reported at least one side effect after each dose. Immunogenicity was evaluated 6 weeks and one year after the second dose. All participants showed increase in their bactericidal titers against the components of the vaccine 6 weeks after the second dose, however titers declined significantly one year later.

Domains

Vaccinology
Fichier principal
Vignette du fichier
Immunogenicity and safety among laboratory workers vaccinated with Bexsero vaccine.pdf (1.07 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Loading...

Dates and versions

pasteur-01579663 , version 1 (31-08-2017)

Licence

Attribution

Identifiers

Cite

Eva Hong, Aude Terrade, Muhamed-Kheir Taha. Human Vaccines & Immunotherapeutics Immunogenicity and safety among laboratory workers vaccinated with Bexsero® vaccine. Human Vaccines & Immunotherapeutics, 2016, ⟨10.1080/21645515.2016.1241358⟩. ⟨pasteur-01579663⟩

Collections

PASTEUR
75 View
179 Download

Altmetric

Share

Gmail Facebook X LinkedIn More